Clinical Trial Update: A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) [Phase 4]

View source ↗

Summary

A Phase 4 head-to-head trial comparing risankizumab with deucravacitinib in moderate plaque psoriasis has completed, aiming to compare safety and efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• SKYRIZI (risankizumab-rzaa)
• Sotyktu (Deucravacitinib)

Snippet

Sponsor: AbbVie | Conditions: Moderate Plaque Psoriasis | Phase 4 | Status: COMPLETED